Measurement of biosynthesis and breakdown rates of biological molecules that are inaccessible or not easily accessible to direct sampling, non-invasively, by label incorporation into metabolic derivatives and catabolic products
View Patent ↗Methods of determining rate of biosynthesis or breakdown of biological molecules from metabolic derivatives and catabolic products are disclosed herein. In particular, methods of measuring the rates of biosynthesis and breakdown of biological molecules inaccessible or not easily accessible to direct sampling by sampling metabolic derivatives and catabolic products in accessible biological samples are disclosed herein.
1. A method for determining the rate of biosynthesis of one or more biological molecules in an individual through the detection of one or more metabolic derivatives of said one or mor biological molecules comprising the steps of:
a) administering an isotope-labeled precursor molecule to said individual for a period of time sufficient for the label of said isotope-labeled precursor molecule to become incorporated into said one or more biological molecules;
b) obtaining one or more biological samples from said individual, wherein said one or more biological samples comprise said one or more metabolic derivatives of said one or more biological molecules as resulting from in vivo metabolism of said biological molecules; and
c) detecting the incorporation of said label in said one or more metabolic derivatives by mass spectrometry to determine said rate of biosynthesis of said one or more biological molecules; wherein said one or more biological molecules are selected from the group consisting of proteins, polynucleotides, lipids, glycosaminoglycans, proteoglycans, and carbohydrates, and wherein said one or more metabolic derivatives comprise polymers that have at least two subunits.
2. The method according to claim 1 wherein said detecting step includes calculating the isotope enrichment of said biological molecule by mass isotopomer distribution analysis (MIDA); and applying precursor-product equations to determine the rate of biosynthesis of said inaccessible biological molecule.
3. The method according to claim 1 wherein the isotopic label is selected from the group consisting of 2 H, 3 H, 13 C, 15 N, 18 O, 3 H, 14 C, 35 S, 32 P, 125 I, and 131 I.
4. The method of claim 3 wherein said label is 2 H.
5. The method of claim 1 wherein said precursor molecule is water.
6. The method according to claim 1 comprising the additional step of purifying said one or more metabolic derivatives from said biological samples before said step (c).
7. The method according to claim 1 wherein said isotope-labeled precursor molecule is administered orally.
8. The method according to claim 1 wherein following said step (b), the method includes the additional step of degrading said one or more metabolic derivatives to form degraded metabolic derivatives.
9. The method according to claim 8 , wherein said degraded metabolic derivatives are further separated by gas chromatography or HPLC.
10. The method according to claim 1 wherein said individual is a human.
11. The method of claim 1 , wherein said metabolic derivatives are catabolic products.
12. The method according to claim 1 wherein said label of said isotope-labeled precursor molecule is incorporated into said one or more biological molecules followed by catabolic breakdown of said one or more biological molecules to form said one or more metabolic derivatives.
13. The method according to claim 1 comprising the additional step of discontinuing said administering step (a).
14. The method according to claim 1 wherein said one or more biological molecules is a protein.
15. The method according to claim 14 wherein said precursor molecule is an amino acid or one or more metabolic precursors of an amino acid.
16. The method according to claim 14 wherein said one or more metabolic derivatives is a peptide.
17. The method according to claim 14 wherein said protein is collagen.
18. The method according to claim 17 wherein said one or more metabolic derivatives includes a collagen-specific metabolic derivative selected from the group consisting of N-terminal telopeptide α1(I) (SEQ ID NO:1), N-terminal telopeptide α 2 (I) (SEQ ID NO:2), N-terminal telopeptide α2(I) (SEQ ID NO:3), N-terminal telopeptide α1(II) (SEQ ID NO:4), N-terminal telopeptide α1(III) (SEQ ID NO:5), C-terminal telopeptide α1(I) (SEQ ID NO:6), C-terminal telopeptide α2(I) (SEQ ID NO:7), C-terminal telopeptide α1(II) (SEQ ID NO:8), C-terminal telopeptide α1(II) (SEQ ID NO:9), C-terminal telopeptide α1(II) (SEQ ID NO:10), C-terminal telopeptide α1(III) (SEQ ID NO:11), cross-linked carboxy-terminal peptide of type I collagen (ICTP), PINP(α1) (SEQ ID NO:12), PICP(α1) (SEQ ID NO:13), PINP(α2) (SEQ ID NO:14), PICP(α2) (SEQ ID NO:15), PIINP(α1) (SEQ ID NO:16), PIICP(α1) (SEQ ID NO:17), PIIINP(α1) (SEQ ID NO:18), PIIICP(α1)(SEQ ID NO:19), PIVNP(α1)(SEQ ID NO:20), PIVNP(α2)(SEQ ID NO:21), PIVNP(α2)(SEQ ID NO:22), PIVNP(α3) (SEQ ID NO:23), PIVNP(α4) (SEQ ID NO:24), PIVNP(α5) (SEQ ID NO:25), and PIVNP(α6) (SEQ ID NO:26).
19. The method of claim 18 wherein said one or more metabolic derivatives are an N-terminal or C-terminal amino acid sequence specific to a type of collagen.
20. The method according to claim 14 wherein said protein is myosin.
21. The method according to claim 14 wherein the said protein is Amyloid Precursor Protein (APP) and said metabolic derivative is an APP-specific metabolic derivative.
22. The method according to claim 21 wherein said APP-specific metabolic derivative is amyloid-beta 1-40 or amyloid-beta 1-42.
23. The method according to claim 14 wherein said one or more metabolic derivatives is a post-translationally modified protein.
24. The method according to claim 23 wherein said post-translationally modified protein is selected from the group consisting of phosphorylated, methylated, hydroxylated, glycosylated, N-acetyl-glucosaminated, prenylated, palmitoylated, and gamma-carboxylated peptides.
25. The method according to claim 14 wherein said protein is myelin basic protein.
26. The method according to claim 25 wherein said protein is brain myelin basic protein.
27. The method according to claim 25 wherein said metabolic derivative is myelin basic protein-like material.
28. The method according to claim 25 wherein said biological sample is urine.
29. The method according to claim 1 , wherein said one or more biological molecules is a lipid.
30. The method according to claim 29 wherein said lipid is a brain membrane lipid.
31. The method of claim 29 wherein said metabolic derivative is selected from the group consisting of 24(s)-hydroxycholesterol, galactosyl-cerebroside, sphingomyelin, and sphingosines.
32. The method according to claim 1 wherein said one or more biological molecules is a polynucleotide.
33. The method according to claim 32 wherein said polynucleotide is deoxyribonucleic acid (DNA).
34. The method according to claim 33 wherein said label is introduced post-replication to said DNA.
35. The method according to claim 32 wherein said one or more metabolic derivatives is a nucleic acid.
36. The method according to claim 1 wherein said precursor molecule is administered repeatedly or continuously before said step (b), wherein said precursor molecule is administered repeatedly or continuously for as long as 4-5 half-lives of the one or more biological molecules.
37. The method of claim 1 , wherein said one or more biological molecules is selected from glycosaminoglycans or proteoglycans.
38. The method of claim 37 , wherein said one or more metabolic derivatives is selected from the group consisting of hyaluronic acid disaccharide, hyaluronic acid polymers, chondroitin-sulfate disaccharide, chondroitin-sulfate polymers, heparin sulfate disaccharide, and heparin sulfate disaccharide polymers.
39. The method of claim 1 wherein said one or more biological molecules cannot be obtained from said individual through a method selected from the group consisting of urine collection, blood drawing and needle aspiration.
40. The method of claim 1 wherein said one or more biological samples is selected from the group consisting of urine, blood, saliva, lachrymal fluid, inflammatory exudates, synovial fluid, abscess, empyema or other infected fluid, cerebrospinal fluid, sweat, pulmonary secretions, sputum, seminal fluid and feces.
41. The method of claim 40 wherein said one or more biological molecules is not present in quantities detectable by mass spectrometry in said one or more biological samples.
42. A method for determining the rate of breakdown of one or more biological molecules in an individual through the detection of one or more metabolic derivatives of said one or more biological molecules comprising the steps of:
a) administering an isotope-labeled precursor molecule to said individual for a period of time sufficient for the label of said isotope-labeled precursor molecule to become incorporated into said one or more biological molecules;
b) discontinuing said administering step;
c) obtaining one or more biological samples from said individual, wherein said one or more biological samples comprise said one or more metabolic derivatives of said one or more biological molecules as resulting from in vivo metabolism of said biological molecules; and
d) detecting the incorporation of said label in said one or more metabolic derivatives by mass spectrometry to determine said rate of breakdown of said one or more biological molecules; wherein said one or more biological molecules are selected from the group consisting of proteins, polynucleotides, lipids, glycosaminoglycans, proteoglycans, and carbohydrates, and wherein said one or more metabolic derivatives comprise polymers that have at least two subunits.